← Back to Search

Home Visiting for Mother and Infant Well-being (MIHOPE Trial)

N/A
Waitlist Available
Led By Virginia Knox, PhD
Research Sponsored by MDRC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
At least 15 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up when focal child is 2.5 years old and when focal child is 3.5 years old
Awards & highlights

MIHOPE Trial Summary

This trial is studying home visiting programs authorized under the Maternal, Infant, and Early Childhood Home Visiting (MIECHV) program to see if they improve outcomes for families.

Who is the study for?
This trial is for pregnant individuals or those with a child under 28 weeks old, at least 15 years of age, and eligible for the home visiting program. It excludes women already in such programs, children in foster care using EHS model sites, homeless families at EHS sites, and non-English/Spanish speakers.Check my eligibility
What is being tested?
The MIHOPE study tests the effectiveness of home visiting services versus community service referrals on family outcomes. It involves over four thousand families across multiple states and uses data from various sources to evaluate these effects.See study design
What are the potential side effects?
Since this trial involves social support interventions rather than medical treatments, traditional side effects are not applicable. However, there may be varying impacts on family dynamics or stress levels.

MIHOPE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 15 years old or older.

MIHOPE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~when focal child is 2.5 years old and when focal child is 3.5 years old
This trial's timeline: 3 weeks for screening, Varies for treatment, and when focal child is 2.5 years old and when focal child is 3.5 years old for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Any child ED use
Any health encounter for injury or ingestion
Behavior problems
+9 more
Other outcome measures
Health status of mother is rated "fair" or "poor"
Maternal depressive symptoms
Mother is pursuing education or training
+3 more

MIHOPE Trial Design

1Treatment groups
Experimental Treatment
Group I: Home visitingExperimental Treatment1 Intervention
Home visiting programs in the United States grew from three major approaches that first became prominent in the 1960s: visits by public health nurses to promote infant and child health in disadvantaged families, Head Start home visiting to promote school readiness in hard-to-reach families, and home-based family support to promote positive parenting and prevent child abuse in high-risk families. All of these approaches sought to foster early childhood health and development by intervening in the home to support and improve socialization, health, and education practices.Today, home visiting is seen as a particularly important strategy for high-risk families who may be difficult to engage in other services.

Find a Location

Who is running the clinical trial?

MDRCLead Sponsor
7 Previous Clinical Trials
14,693 Total Patients Enrolled
Mathematica Policy Research, Inc.OTHER
57 Previous Clinical Trials
6,114,261 Total Patients Enrolled
University of GeorgiaOTHER
100 Previous Clinical Trials
30,426 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings still available for this clinical trial?

"The clinicaltrials.gov listing for this trial indicates that it is not accepting participants currently; the trial was first posted on October 1st 2012 and recently updated April 4th 2022. However, there are 110 other studies seeking volunteers at present."

Answered by AI
~339 spots leftby Apr 2025